Cardiovascular Systems Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: August-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
Abbott is the sole owner, so capital and portfolio decisions now sit with Abbott management and its board rather than former CSII shareholders. This is the central issue in control and governance because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.Robert Ford leads the business and Robert Ford chairs or represents the governing board. The owner field records Abbott Laboratories at 100%, so formal percentages must be read beside voting rights and contractual authority. The practical test is whether directors challenge management when strategic ambition conflicts with owner returns. Disclosure should make relevant tradeoffs visible rather than forcing investors to infer them from headline results.The downside case is concrete: clinical outcomes, reimbursement, physician training, device recalls, competing calcium-modification technologies and integration priorities can limit returns. I would not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to the board. A credible plan must specify triggers for reducing spending, leverage or complexity.The $851 million purchase price represented a strategic premium for complementary atherectomy technology and established physician adoption. A governance premium is earned only when independent oversight reduces agency risk and protects capital through a cycle. Investors should compare implied expectations with achievable cash returns and avoid paying for targets that have not survived a full operating cycle. Scenario analysis should include weaker demand and higher funding costs.I would tie executive rewards to per-share or owner value, balance-sheet resilience and clearly measured strategic outcomes. I would judge the deal on incremental procedure growth, cross-selling and clinical outcomes rather than preserving the former standalone corporate footprint. My view is that Cardiovascular Systems deserves a premium only when management demonstrates measurable value creation after all operating, financing and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Former institutional holders were cashed out in 2023, and current economic exposure comes through Abbott's much broader shareholder register. This is the central issue in shareholder composition and capital-market behavior because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The institutional register lists The Vanguard Group, BlackRock, State Street Corporation at 9.8%, 7.8%, 4.4%. These holders influence elections, liquidity or private control, but they do not guarantee a common view on strategy or risk. The practical test is whether directors challenge management when strategic ambition conflicts with owner returns. Disclosure should make relevant tradeoffs visible rather than forcing investors to infer them from headline results.The downside case is concrete: clinical outcomes, reimbursement, physician training, device recalls, competing calcium-modification technologies and integration priorities can limit returns. I would not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to the board. A credible plan must specify triggers for reducing spending, leverage or complexity.The $851 million purchase price represented a strategic premium for complementary atherectomy technology and established physician adoption. Stable institutions or sponsors can reduce financing uncertainty, but concentration cannot substitute for durable operating results or engaged directors. Investors should compare implied expectations with achievable cash returns and avoid paying for targets that have not survived a full operating cycle. Scenario analysis should include weaker demand and higher funding costs.I would expect major holders to press for transparent capital priorities, credible downside planning and disciplined compensation. I would judge the deal on incremental procedure growth, cross-selling and clinical outcomes rather than preserving the former standalone corporate footprint. My view is that Cardiovascular Systems deserves a premium only when management demonstrates measurable value creation after all operating, financing and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|
Portfolio Analysis
Device names retain physician recognition, but their strategic value now depends on integration with Abbott's guidewires, balloons, imaging and stents. This is the central issue in brand and portfolio strategy because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The portfolio includes Diamondback 360, Stealth 360, ViperWire, WIRION, Peripheral OAS and Coronary OAS. Each identity should have a defined customer promise and economic role, with shared capabilities producing measurable benefits rather than administrative complexity. The practical test is whether directors challenge management when strategic ambition conflicts with owner returns. Disclosure should make relevant tradeoffs visible rather than forcing investors to infer them from headline results.The downside case is concrete: clinical outcomes, reimbursement, physician training, device recalls, competing calcium-modification technologies and integration priorities can limit returns. I would not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to the board. A credible plan must specify triggers for reducing spending, leverage or complexity.The $851 million purchase price represented a strategic premium for complementary atherectomy technology and established physician adoption. A portfolio premium requires evidence that customer trust, technical know-how or distribution produces stronger retention and margins. Investors should compare implied expectations with achievable cash returns and avoid paying for targets that have not survived a full operating cycle. Scenario analysis should include weaker demand and higher funding costs.I would invest behind identities with the strongest incremental returns and simplify offerings that do not reinforce customer advantage. I would judge the deal on incremental procedure growth, cross-selling and clinical outcomes rather than preserving the former standalone corporate footprint. My view is that Cardiovascular Systems deserves a premium only when management demonstrates measurable value creation after all operating, financing and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|
Competitive Analysis
Orbital atherectomy offers a differentiated mechanism, yet lithotripsy and other vessel-preparation technologies can shift clinical preferences. This is the central issue in competitive position and valuation because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The current performance base is standalone fiscal 2022 revenue of $236.2 million and 725 employees before Abbott acquired the company in April 2023. Competitive strength should be tested through pricing, retention, market share, unit economics and return on invested capital rather than broad claims about addressable markets. The practical test is whether directors challenge management when strategic ambition conflicts with owner returns. Disclosure should make relevant tradeoffs visible rather than forcing investors to infer them from headline results.The downside case is concrete: clinical outcomes, reimbursement, physician training, device recalls, competing calcium-modification technologies and integration priorities can limit returns. I would not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to the board. A credible plan must specify triggers for reducing spending, leverage or complexity.The $851 million purchase price represented a strategic premium for complementary atherectomy technology and established physician adoption. A competitive premium should follow sustainable cash economics and reinvestment opportunity, not one favorable period or a temporary shortage. Investors should compare implied expectations with achievable cash returns and avoid paying for targets that have not survived a full operating cycle. Scenario analysis should include weaker demand and higher funding costs.I would track leading indicators of pricing power and retention before assuming any cyclical improvement is permanent. I would judge the deal on incremental procedure growth, cross-selling and clinical outcomes rather than preserving the former standalone corporate footprint. My view is that Cardiovascular Systems deserves a premium only when management demonstrates measurable value creation after all operating, financing and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|
Acquisitions Analysis
Abbott bought a whole company rather than licensing one device, accepting manufacturing, clinical, regulatory and employee integration obligations. This is the central issue in acquisition discipline and integration because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The transaction record matters because abbott funds product development, manufacturing, clinical evidence and commercialization within its much larger medical-device balance sheet. Management should publish post-deal scorecards comparing promised economics with retention, margins, cash conversion and financing costs. The practical test is whether directors challenge management when strategic ambition conflicts with owner returns. Disclosure should make relevant tradeoffs visible rather than forcing investors to infer them from headline results.The downside case is concrete: clinical outcomes, reimbursement, physician training, device recalls, competing calcium-modification technologies and integration priorities can limit returns. I would not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to the board. A credible plan must specify triggers for reducing spending, leverage or complexity.The $851 million purchase price represented a strategic premium for complementary atherectomy technology and established physician adoption. Deal-driven growth warrants a premium only when acquired cash flows exceed financing, integration and opportunity costs under conservative assumptions. Investors should compare implied expectations with achievable cash returns and avoid paying for targets that have not survived a full operating cycle. Scenario analysis should include weaker demand and higher funding costs.I would require a conservative base case, an explicit failure case and a formal post-close review before approving another material transaction. I would judge the deal on incremental procedure growth, cross-selling and clinical outcomes rather than preserving the former standalone corporate footprint. My view is that Cardiovascular Systems deserves a premium only when management demonstrates measurable value creation after all operating, financing and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
The 2007 reverse merger created public currency, while the 2023 sale ended independent reporting and concentrated strategic choices inside Abbott. This is the central issue in merger, spinoff and structural history because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.Cardiovascular Systems became publicly traded through a 2007 reverse merger and operated independently until Abbott completed its acquisition on April 27, 2023. Abbott paid $20 per share, recording a purchase price of $851 million. The former CSII shares were delisted, and the atherectomy portfolio became part of Abbott's vascular device operations. Today's segments, leverage and strategic choices are direct consequences of those structural decisions. The practical test is whether directors challenge management when strategic ambition conflicts with owner returns. Disclosure should make relevant tradeoffs visible rather than forcing investors to infer them from headline results.The downside case is concrete: clinical outcomes, reimbursement, physician training, device recalls, competing calcium-modification technologies and integration priorities can limit returns. I would not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to the board. A credible plan must specify triggers for reducing spending, leverage or complexity.The $851 million purchase price represented a strategic premium for complementary atherectomy technology and established physician adoption. Structural change creates value only when accountability, focus or cash generation improves after tax, financing and integration costs. Investors should compare implied expectations with achievable cash returns and avoid paying for targets that have not survived a full operating cycle. Scenario analysis should include weaker demand and higher funding costs.I would support another structural move only if quantified benefits exceed integration cost, leverage and lost flexibility. I would judge the deal on incremental procedure growth, cross-selling and clinical outcomes rather than preserving the former standalone corporate footprint. My view is that Cardiovascular Systems deserves a premium only when management demonstrates measurable value creation after all operating, financing and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Ownership History
Ownership History Analysis
The ownership arc delivered liquidity to former shareholders, but Abbott must still earn the premium through durable procedure and portfolio economics. This is the central issue in ownership and strategic evolution because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The defining arc is an independent orbital atherectomy pioneer becoming a wholly owned Abbott vascular technology platform. Heritage supports credibility only when its best operating lessons remain embedded in incentives, succession and capital discipline. The practical test is whether directors challenge management when strategic ambition conflicts with owner returns. Disclosure should make relevant tradeoffs visible rather than forcing investors to infer them from headline results.The downside case is concrete: clinical outcomes, reimbursement, physician training, device recalls, competing calcium-modification technologies and integration priorities can limit returns. I would not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to the board. A credible plan must specify triggers for reducing spending, leverage or complexity.The $851 million purchase price represented a strategic premium for complementary atherectomy technology and established physician adoption. Historical success informs judgment but cannot be capitalized indefinitely when leadership, technology or industry structure changes. Investors should compare implied expectations with achievable cash returns and avoid paying for targets that have not survived a full operating cycle. Scenario analysis should include weaker demand and higher funding costs.I would preserve capabilities that created the franchise while discarding legacy practices that no longer earn adequate returns. I would judge the deal on incremental procedure growth, cross-selling and clinical outcomes rather than preserving the former standalone corporate footprint. My view is that Cardiovascular Systems deserves a premium only when management demonstrates measurable value creation after all operating, financing and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Ownership Explained
Cardiovascular Systems is not independently exchange-listed and its parent or controlling owner is Abbott Laboratories. Robert Ford leads the business and Robert Ford chairs or represents the governing board. Ownership percentages must be read with voting rights, merger agreements and contractual authority.The operating model is Abbott's orbital atherectomy portfolio for preparing calcified coronary and peripheral vessels before angioplasty or stenting. Important owned identities include Diamondback 360, Stealth 360, ViperWire, WIRION, Peripheral OAS and Coronary OAS. These businesses share capital, risk oversight and strategic direction even when customer relationships remain attached to product, local or specialist names.The latest annual record includes standalone fiscal 2022 revenue of $236.2 million and 725 employees before Abbott acquired the company in April 2023. Full-year figures are the cleanest scale reference because quarters can be distorted by seasonality, transaction timing, purchase accounting or volatile end markets. Investors should still reconcile revenue with free cash flow and balance-sheet change.Abbott funds product development, manufacturing, clinical evidence and commercialization within its much larger medical-device balance sheet. In my view, the decisive ownership question is how management and the governing board allocate cash and strategic attention. A shareholder list is descriptive, while capital-allocation outcomes reveal who benefits from control.
Private or subsidiary ownership shapes disclosure, financing flexibility and management accountability at Cardiovascular Systems. The governing board must convert control and access to capital into durable value and should not treat revenue growth, asset count or transaction volume as ends in themselves.clinical outcomes, reimbursement, physician training, device recalls, competing calcium-modification technologies and integration priorities can limit returns. Owners and stakeholders therefore need operating indicators that reveal whether the franchise is strengthening before reported earnings fully reflect the change. Balance-sheet resilience is part of ownership quality because it preserves strategic choice during stress.The $851 million purchase price represented a strategic premium for complementary atherectomy technology and established physician adoption. This context raises the hurdle for every acquisition, repurchase, development program or restructuring decision. Management should compare each use of funds against debt reduction and the value of retaining liquidity.I would judge the deal on incremental procedure growth, cross-selling and clinical outcomes rather than preserving the former standalone corporate footprint. That discipline is what ownership means in practice for investors, employees, customers and creditors. The enterprise deserves confidence only when governance converts control into transparent, repeatable cash returns.